EOLS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -8.6% compared to Evolus's net margin of 12.11%. Evolus's return on equity of -885.18% beat Electromed's return on equity of 15.91%.

Evolus has a consensus price target of $24.14, signalling upside risk potential of 79.23%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.71%. Given that Evolus has higher upside potential than Electromed, analysts believe Evolus is more attractive than Electromed.

Evolus has a beta of 1.280, which suggesting that the stock is 27.999% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $78.9M, which are larger than Electromed quarterly revenues of $16.3M. Evolus's net income of -$6.8M is lower than Electromed's net income of $2M. Notably, Evolus's price-to-earnings ratio is -- while Electromed's PE ratio is 32.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 3.14x versus 3.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -8.6% compared to Evolus's net margin of -1226.82%. Evolus's return on equity of -885.18% beat VolitionRX's return on equity of --.

Evolus has a consensus price target of $24.14, signalling upside risk potential of 79.23%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 505.63%. Given that VolitionRX has higher upside potential than Evolus, analysts believe VolitionRX is more attractive than Evolus.

Evolus has a beta of 1.280, which suggesting that the stock is 27.999% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $78.9M, which are larger than VolitionRX quarterly revenues of $474.5K. Evolus's net income of -$6.8M is lower than VolitionRX's net income of -$5.8M. Notably, Evolus's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 3.14x versus 35.95x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -8.6% compared to Evolus's net margin of 17.38%. Evolus's return on equity of -885.18% beat West Pharmaceutical Services's return on equity of 18.15%.

Evolus has a consensus price target of $24.14, signalling upside risk potential of 79.23%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that Evolus has higher upside potential than West Pharmaceutical Services, analysts believe Evolus is more attractive than West Pharmaceutical Services.

Evolus has a beta of 1.280, which suggesting that the stock is 27.999% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Evolus pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evolus quarterly revenues are $78.9M, which are smaller than West Pharmaceutical Services quarterly revenues of $748.8M. Evolus's net income of -$6.8M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Evolus's price-to-earnings ratio is -- while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 3.14x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -8.6% compared to Evolus's net margin of -10.04%. Evolus's return on equity of -885.18% beat Xtant Medical Holdings's return on equity of -35.34%.

Evolus has a consensus price target of $24.14, signalling upside risk potential of 79.23%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than Evolus, analysts believe Xtant Medical Holdings is more attractive than Evolus.

Evolus has a beta of 1.280, which suggesting that the stock is 27.999% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Evolus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Evolus quarterly revenues are $78.9M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Evolus's net income of -$6.8M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Evolus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus is 3.14x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.